v3 Template
C

CRISPR Therapeutics

Biotechnology ZUG, Switzerland and BOSTON ~135 employees
Founded
--
Employees (Est.)
~135
9 leaders known
Total Funding
$1.2B
Funding Rounds
3
Last Funding
2026-03-11

About CRISPR Therapeutics

CRISPR Therapeutics is a pioneering company focused on transforming the lives of patients with serious diseases through innovative gene-editing technologies. With over a decade of innovation, they aim to rapidly translate revolutionary CRISPR technology into therapies across a broad range of disease areas.

Products & Services

CASGEVY™ (exagamglogene autotemcel):A CRISPR/Cas9 gene-edited therapy approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia, developed in collaboration with Vertex Pharmaceuticals Incorporated.
Therapies and Pipeline:A diverse portfolio of therapies targeting hemoglobinopathies, oncology, diabetes, and cardiovascular disease, including 1 approved therapy, 5 clinical programs, and 10 preclinical programs.

Specialties

Gene Editing CRISPR Technology Hemoglobinopathies Immuno-Oncology Autoimmune Diseases In Vivo Gene Editing Regenerative Medicine CRISPR-X

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Debt
T: -
FT: Debt
A: 550000000
MR: -
FA: $550 million
FAN: 550000000
D: 2026-03-11
FD: 2026-03-11
-
2 RT: Convertible Senior Notes
T: -
FT: Convertible Senior Notes
A: 350000000
MR: -
FA: 350 million
FAN: 350000000
D: 2026-03-10
FD: 2026-03-10
-
3 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 280000000
MR: -
FA: 280 million
FAN: 280000000
D: 2024-02-13
FD: 2024-02-13
2 investors
Debt Latest
2026-03-11
$550.0M
Convertible Senior Notes 2026-03-10
$350.0M
Registered Direct Offering 2024-02-13
$280.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

S

Samarth Kulkarni

Chief Executive Officer and Chairman of the Board

J

James R. Kasinger

General Counsel and Secretary

S

Stephen Kennedy

Head of Technical Operations

M

Megan Wherry Menner

Head of Human Resources

N

Naimish Patel

Chief Medical Officer

R

Raju Prasad

Chief Financial Officer

View 6 more team members with Pro

Unlock Full Team Directory

Recent News

CRISPR Therapeutics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology
Company Size
~135 employees (est.)
Locations
ZUG, Switzerland and BOSTON
Zug, Switzerland and Boston, Massachusetts
Zug, Switzerland

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro